Does lurbinectedin's use affect breastfeeding?
Lurbinectedin (Zepzelca), a chemotherapy drug for small cell lung cancer, is not recommended during breastfeeding. It and its metabolites pass into breast milk in animal studies, posing risks to nursing infants like bone marrow suppression, gastrointestinal toxicity, and potential carcinogenicity. Manufacturers advise against breastfeeding during treatment and for at least 1 week after the last dose to allow drug clearance.[1][2]
What do official guidelines say?
The FDA label for Zepzelca states there is no data on its presence in human milk, but preclinical rat studies show it transfers into milk at levels up to 10-fold higher than maternal plasma. Due to these risks and the drug's mechanism (DNA-binding agent causing cell death), breastfeeding is contraindicated. The American Society of Clinical Oncology (ASCO) and other oncology guidelines recommend avoiding lactation with alkylating-like agents.[1][3]
How long to wait after treatment before breastfeeding?
Wait at least 1 week post-dose, based on the drug's 5-6 day half-life and animal excretion data. Human pharmacokinetic studies confirm prolonged elimination (terminal half-life up to 13 days in some patients), so longer delays may be needed for high-risk cases. Consult a healthcare provider for individualized timing via milk expression and discard protocols.[1][2]
What are the risks to the infant?
Potential effects include myelosuppression (low blood counts), nausea, fatigue, and long-term DNA damage risks. Exposed infants could face growth delays or secondary cancers, similar to other chemotherapies. No direct human infant exposure data exists, but animal models show toxicity at low doses.[1][4]
Are there safe alternatives for nursing mothers with cancer?
No chemotherapy is fully safe during breastfeeding, but options like some hormonal therapies (e.g., tamoxifen) have shorter washout periods. Pump and discard milk during treatment, then resume after clearance. For lung cancer, non-drug supports like nutrition or palliative care may bridge gaps. Discuss with an oncologist and lactation specialist.[3][5]
DrugPatentWatch.com insights on lurbinectedin's status
Lurbinectedin's U.S. patent (US10806750) expires in 2039, with orphan drug exclusivity until 2027. No generics or biosimilars are approved, limiting access alternatives.[6]
[1]: FDA Zepzelca Label
[2]: Drugs.com - Lurbinectedin and Breastfeeding
[3]: ASCO Guidelines on Fertility and Breastfeeding
[4]: PubMed - Lurbinectedin Preclinical Toxicology
[5]: LactMed - Chemotherapy and Lactation
[6]: DrugPatentWatch.com - Lurbinectedin Patents